Envestnet Asset Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-41,216
| Closed | -$1.18M | – | 4294 |
|
|
2024
Q2 | $1.18M | Sell |
41,216
-2,054
| -5% | -$58.5K | ﹤0.01% | 2923 |
|
|
2024
Q1 | $1.26M | Buy |
43,270
+7,342
| +20% | +$226K | ﹤0.01% | 2869 |
|
|
2023
Q4 | $1.21M | Buy |
35,928
+2,514
| +8% | +$73.6K | ﹤0.01% | 2800 |
|
|
2023
Q3 | $1.03M | Sell |
33,414
-779
| -2% | -$28.1K | ﹤0.01% | 2798 |
|
|
2023
Q2 | $1.37M | Sell |
34,193
-553
| -2% | -$22.9K | ﹤0.01% | 2523 |
|
|
2023
Q1 | $1.42M | Buy |
34,746
+13,202
| +61% | +$525K | ﹤0.01% | 2419 |
|
|
2022
Q4 | $832K | Sell |
21,544
-4,254
| -16% | -$207K | ﹤0.01% | 2779 |
|
|
2022
Q3 | $1.37M | Sell |
25,798
-124
| -0.5% | -$6.9K | ﹤0.01% | 2316 |
|
|
2022
Q2 | $1.51M | Sell |
25,922
-992
| -4% | -$65K | ﹤0.01% | 2290 |
|
|
2022
Q1 | $2.05M | Buy |
26,914
+1,516
| +6% | +$101K | ﹤0.01% | 2177 |
|
|
2021
Q4 | $1.53M | Buy |
25,398
+1,866
| +8% | +$103K | ﹤0.01% | 2338 |
|
|
2021
Q3 | $1.32M | Buy |
23,532
+6,007
| +34% | +$346K | ﹤0.01% | 2366 |
|
|
2021
Q2 | $1.06M | Buy |
17,525
+515
| +3% | +$32.6K | ﹤0.01% | 2484 |
|
|
2021
Q1 | $1.19M | Buy |
17,010
+3,301
| +24% | +$236K | ﹤0.01% | 2271 |
|
|
2020
Q4 | $820K | Buy |
13,709
+818
| +6% | +$47.9K | ﹤0.01% | 2356 |
|
|
2020
Q3 | $775K | Buy |
12,891
+8,033
| +165% | +$467K | ﹤0.01% | 2182 |
|
|
2020
Q2 | $255K | Buy |
+4,858
| New | +$203K | ﹤0.01% | 2760 |
|
|
2020
Q1 | – | Sell |
-7,295
| Closed | -$330K | – | 3094 |
|
|
2019
Q4 | $330K | Buy |
+7,295
| New | +$310K | ﹤0.01% | 2691 |
|
|
2019
Q3 | – | Sell |
-5,588
| Closed | -$243K | – | 3142 |
|
|
2019
Q2 | $243K | Buy |
+5,588
| New | +$237K | ﹤0.01% | 2799 |
|
|
2018
Q3 | – | Sell |
-1,267
| Closed | -$41K | – | 2208 |
|
|
2018
Q2 | $41K | Sell |
1,267
-89
| -7% | -$3.07K | ﹤0.01% | 2259 |
|
|
2018
Q1 | $42K | Sell |
1,356
-481
| -26% | -$17.1K | ﹤0.01% | 2192 |
|
|
2017
Q4 | $83K | Sell |
1,837
-72
| -4% | -$2.85K | ﹤0.01% | 2160 |
|
|
2017
Q3 | $72K | Buy |
1,909
+513
| +37% | +$20.6K | ﹤0.01% | 2186 |
|
|
2017
Q2 | $67K | Buy |
1,396
+1,299
| +1,339% | +$60.3K | ﹤0.01% | 2265 |
|
|
2017
Q1 | $4K | Sell |
97
-24
| -20% | -$1.04K | ﹤0.01% | 2932 |
|
|
2016
Q4 | $4K | Buy |
+121
| New | +$4.04K | ﹤0.01% | 2916 |
|
|
2016
Q2 | – | Sell |
-1,437
| Closed | -$76K | – | 3125 |
|
|
2016
Q1 | $76K | Buy |
+1,437
| New | +$84.1K | ﹤0.01% | 2534 |
|
|
2014
Q4 | – | Sell |
-26
| Closed | -$3K | – | 2663 |
|
|
2014
Q3 | $3K | Buy |
26
+16
| +160% | +$1.56K | ﹤0.01% | 2429 |
|
|
2014
Q2 | $1K | Buy |
+10
| New | +$761 | ﹤0.01% | 2615 |
|
Other funds holding PCRX
DPCM
Envestnet Asset Management's PCRX Position: Q3 2024 in Review
Envestnet Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 41,216 shares — an estimated $1.18M sold.
Envestnet Asset Management first reported a position in PCRX in Q2 2014 and held it in 29 quarters. The position peaked at $2.05M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.
- Envestnet Asset Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
- Envestnet Asset Management sold 41,216 Pacira BioSciences shares in Q3 2024, an estimated $1.18M.
- Envestnet Asset Management first reported a position in Pacira BioSciences in Q2 2014 and held it in 29 quarters.
- Envestnet Asset Management's Pacira BioSciences position peaked at $2.05M in Q1 2022.
- 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.
Based on Envestnet Asset Management's 13F filing for Q3 2024, filed 7 Nov 2024.